Crispr Therapeutics AG plans to launch an initial public offering to raise up to $90 million, according to a late Friday filing with the Securities and Exchange Commission. Basel, Switzerland-based Crispr develops therapies based on its eponymous gene-editing technology. For the six months of 2016, the company reported collaboration revenue of $1.3 million and a loss of $4.66 a share. Crispr listed Citigroup, Piper Jaffray, Barclays, and Guggenheim Securities as underwriters. The company plans to list on the Nasdaq Global markets exchange under the ticker symbol “CRSP”.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News